Minimally invasive heart procedures like transcatheter aortic valve replacement (TAVR) and MitraClip placement to treat mitral regurgitation can improve quality of life, and even be lifesaving, for ...

CHANDIGARH: 87 years old, Tara Chand (name changed), resident of Panchkula, had undergone a non-surgical procedure for aortic ...

The tricuspid valve is anatomically complex. It’s often called the “forgotten valve” because of its position in the back of ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Aortic stenosis is fairly uncommon among young people, though not absent. In younger folks, the disease is typically caused by a congenital heart condition. As we age, calcium deposits can build up ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Despite guideline recommendations, the use of bioprosthetic heart valves has surpassed mechanical valves, but data from a ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

February is American Heart Month. Sister Bay’s David Lienau wasn’t even aware that his heart health was in jeopardy. But ...

The firm remains on the leading edge with the dominant balloon-expanded Sapien transcatheter aortic valve. It is also in a strong position to commercialize transcatheter mitral repair and ...

Edwards Lifesciences beat Q4 estimates with $1.39B in sales, driven by growth in TMTT, TAVR, and Surgical. The company ...

The Heart Valve Devices Market is driven by advancements in aortic, mitral, tricuspid, and pulmonary valve technologies. It ...